Publication: Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC
Loading...
Program
relationships.isAuthorOf
Author
Kilickap, S.
Sezer, A.
Gumus, M.
Bondarenko, I.
Ozguroglu, M.
Turk, H. M.
Bentsion, D.
Gladkov, O.
Clingan, P.
Advisor
Language
Type
Publisher
Journal Title
Journal ISSN
Volume Title
Abstract
Description
Source
Keywords
Keywords
Citation
Kilickap S., Sezer A., Gumus M., Bondarenko I., Ozguroglu M., Gogishvili M., Turk H. M. , Cicin I., Bentsion D., Gladkov O., et al., -Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC-, JOURNAL OF THORACIC ONCOLOGY, cilt.16, sa.3, 2021